> top > docs > PubMed:32357553 > annotations

PubMed:32357553 JSONTXT

Annnotations TAB JSON ListView MergeView

PubMed_ArguminSci

Id Subject Object Predicate Lexical cue
T1 106-260 DRI_Background denotes In January 2020, Chinese health agencies reported an outbreak of a novel coronavirus-2 (CoV-2) which can lead to severe acute respiratory syndrome (SARS).
T2 261-435 DRI_Background denotes The virus, which belongs to the coronavirus family (SARS-CoV-2), was named coronavirus disease 2019 (COVID-19) and declared a pandemic by the World Health Organization (WHO).
T3 436-588 DRI_Approach denotes Full-length genome sequences of SARS-CoV-2 showed 79.6% sequence identity to SARS-CoV, with 96% identity to a bat coronavirus at the whole-genome level.
T4 589-703 DRI_Background denotes COVID-19 has caused over 133,000 deaths and there are over 2 million total confirmed cases as of April 15th, 2020.
T5 704-801 DRI_Background denotes Current treatment plans are still under investigation due to a lack of understanding of COVID-19.
T6 802-974 DRI_Challenge denotes One potential mechanism to slow disease progression is the use of antiviral drugs to either block the entry of the virus or interfere with viral replication and maturation.
T7 975-1137 DRI_Background denotes Currently, antiviral drugs, including chloroquine/hydroxychloroquine, remdesivir, and lopinavir/ritonavir, have shown effective inhibition of SARS-CoV-2 in vitro.
T8 1138-1269 DRI_Background denotes Due to the high dose needed and narrow therapeutic window, many patients are experiencing severe side effects with the above drugs.
T9 1270-1395 DRI_Background denotes Hence, repurposing these drugs with a proper formulation is needed to improve the safety and efficacy for COVID-19 treatment.
T10 1396-1476 DRI_Approach denotes Extracellular vesicles (EVs) are a family of natural carriers in the human body.
T11 1477-1534 DRI_Background denotes They play a critical role in cell-to-cell communications.
T12 1535-1624 DRI_Outcome denotes EVs can be used as unique drug carriers to deliver protease inhibitors to treat COVID-19.
T13 1625-1716 DRI_Outcome denotes EVs may provide targeted delivery of protease inhibitors, with fewer systemic side effects.
T14 1717-1821 DRI_Approach denotes More importantly, EVs are eligible for major aseptic processing and can be upscaled for mass production.
T15 1822-1963 DRI_Challenge denotes Currently, the FDA is facilitating applications to treat COVID-19, which provides a very good chance to use EVs to contribute in this combat.

LitCovid-OGER-BB

Id Subject Object Predicate Lexical cue
T1 48-61 GO:1903561 denotes Extracellular
T2 62-70 GO:1903561 denotes Vesicles
T3 96-104 SP_7 denotes COVID-19
T4 179-190 NCBITaxon:11118 denotes coronavirus
T5 232-243 UBERON:0001004 denotes respiratory
T6 254-258 SP_10 denotes SARS
T7 265-270 NCBITaxon:10239 denotes virus
T8 293-304 NCBITaxon:11118 denotes coronavirus
T9 313-323 SP_7 denotes SARS-CoV-2
T10 336-347 NCBITaxon:11118 denotes coronavirus
T11 362-370 SP_7 denotes COVID-19
T12 448-454 SO:0001026 denotes genome
T13 468-478 SP_7 denotes SARS-CoV-2
T14 513-521 SP_10 denotes SARS-CoV
T15 546-549 SP_2 denotes bat
T16 550-561 NCBITaxon:11118 denotes coronavirus
T17 575-581 SO:0001026 denotes genome
T18 589-597 SP_7 denotes COVID-19
T19 622-628 GO:0016265 denotes deaths
T20 792-800 SP_7 denotes COVID-19
T21 868-883 CHEBI:36044 denotes antiviral drugs
T22 868-883 CHEBI:36044 denotes antiviral drugs
T23 904-912 GO:0035376 denotes entry of
T24 917-922 NCBITaxon:10239 denotes virus
T25 941-946 NCBITaxon:10239 denotes viral
T26 941-958 GO:0006260 denotes viral replication
T27 986-1001 CHEBI:36044 denotes antiviral drugs
T28 986-1001 CHEBI:36044 denotes antiviral drugs
T29 1013-1024 CHEBI:3638 denotes chloroquine
T30 1013-1024 CHEBI:3638 denotes chloroquine
T31 1013-1024 DG_10 denotes chloroquine
T32 1025-1043 CHEBI:5801 denotes hydroxychloroquine
T33 1025-1043 CHEBI:5801 denotes hydroxychloroquine
T34 1025-1043 DG_20 denotes hydroxychloroquine
T35 1045-1055 DG_28 denotes remdesivir
T36 1045-1055 NCBITaxon:11632 denotes remdesivir
T37 1061-1070 CHEBI:31781 denotes lopinavir
T38 1061-1070 CHEBI:31781 denotes lopinavir
T39 1061-1070 DG_23 denotes lopinavir
T40 1071-1080 DG_30 denotes ritonavir
T41 1117-1127 SP_7 denotes SARS-CoV-2
T42 1263-1268 CHEBI:23888 denotes drugs
T43 1263-1268 CHEBI:23888 denotes drugs
T44 1295-1300 CHEBI:23888 denotes drugs
T45 1295-1300 CHEBI:23888 denotes drugs
T46 1376-1384 SP_7 denotes COVID-19
T47 1396-1418 GO:1903561 denotes Extracellular vesicles
T48 1465-1470 SP_6 denotes human
T49 1465-1470 NCBITaxon:9606 denotes human
T50 1561-1565 CHEBI:23888 denotes drug
T51 1561-1565 CHEBI:23888 denotes drug
T52 1595-1605 CHEBI:37670 denotes inhibitors
T53 1595-1605 CHEBI:37670 denotes inhibitors
T54 1615-1623 SP_7 denotes COVID-19
T55 1671-1681 CHEBI:37670 denotes inhibitors
T56 1671-1681 CHEBI:37670 denotes inhibitors
T57 1879-1887 SP_7 denotes COVID-19